Tripos launches new drug discovery platform
Tripos has created compound sets that contain novel, selective inhibitors with demonstrated potency and selectivity toward G-protein-coupled receptors (GPCRs) and kinases, and have the potential to generate new
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.